Pfizer announces strong Phase III results for atopic dermatitis drug
pharmafile | July 14, 2016 | News story | Research and Development | Pfizer, anacor, atopic dermatitis, crisaborole, eczema
Pfizer (NYSE: PFE) has announced positive results from two pivotal Phase III studies for crisaborole in the treatment of mild to moderate atopic dermatitis.
The company acquired the investigational compound as part of their $5.2 billion takeover of Anacor Pharmaceuticals in May. Crisaborole is a differentiated non-steroidal topical PED4 inhibitor with anti-inflammatory properties. At the time of the takeover, Pfizer indicated its peak sales could have the potential to reach or exceed $2 billion.
In these Phase III trials, the results of which were published in the Journal of the American Academy of Dermatology, the drug achieved statistically significant results on primary and secondary endpoints, including patient’s investigator static global assessment (ISGA) score, and changes in baseline of dermatitis rating.
Amy Paller, professor of paediatrics at Northwestern University, says: “Atopic dermatitis, or eczema, is a chronic, inflammatory skin disease that affects millions of children and adults. There have been no new therapies approved in the US for people with atopic dermatitis in the last 15 years. The results seen in these pivotal Phase III studies demonstrated that crisaborole, if approved, could be a meaningful treatment option for patients with mild to moderate atopic dermatitis.”
Sean Murray
Related Content
Sanofi shares phase 2b results for dermatitis treatment
Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …
Pfizer’s Velsipity approved by EC for ulcerative colitis treatment
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) …
InnoCare shares results from phase 2 trial for atopic dermatitis treatment
InnoCare Pharma has announced phase 2 clinical trial results for its novel TYK2 (tyrosine kinase …